US/UK/Canada

Share

Quotes

“The surgery was done by the book by Mr Paul Culpan. We’re delighted to be collaborating with him, The London Clinic and London International Patient Services. It’s an exciting restart for the OPRA™ Implant System program in the U.K. and we hope that this surgery will pave the way for a deeper collaboration moving forward.
Professor Rickard Brånemark
...the treatment of thumb amputees using bone-anchored percutaneous prostheses with the osseointegration technique seems to be a safe, durable method with excellent short- and medium-long follow-up results.
JAAOS study
Osseointegration is a potentially game changing technology in amputee care, and Dr Brånemark is bringing the most advanced osseointegration technology to our group
Professor Hugh Herr, Head of the MIT Media Lab Biomechatronics Group
We are very happy to have Blake join us to strengthen our team and our presence in the hugely important North American market.
Rutger Barrdahl, CEO at Integrum
Pick a time period -
Tags ( Active)

Osseointegration for Amputees Makes its Education Forum Debut at OTA 2024

Integrum AB (publ), ticker INTEG, the medical technology company that provides the bone-anchored OPRA® Implant System to amputees announces its education forum debut.Integrum’s U.S. team recently exhibited at the Orthopedic Trauma Association (OTA) annual meeting, held last week in Montreal. Presented to attendees was a half-day educational forum titled “The Future is Now: Osseointegration for Amputation Reconstruction,” moderated by Dr. Joseph Hsu, one of Integrum’s lead surgeons. This forum marked the first time an osseointegration symposium has been included in the OTA educational

Ty Hanners appointed Director of Sales, US, focused on OPRA Implant System for Amputees

Integrum AB (publ), ticker INTEG, the medical technology company that provides the bone-anchored OPRA implant system to amputees, announces that Ty Hanners has been appointed Director of Sales, US, focused on expanding the OPRA surgical system product offering to amputees. He will start on October 14, 2024.Ty Hanners is a results-oriented sales leader with over 20 years in the prosthetic and orthopedic implant industry. He most recently served as a sales leader at Willowood Inc. and has past experience at Össur and Xtremity, innovative prosthetic and medical companies. Ty will be focused on

Join Us for an Investor Update Online with our Acting CEO Scott Flora

Integrum AB (publ), the medical technology company that improves the lives of amputees, cordially invites you to an online investor information session on September 25, 2024, @ 3 pm CEST.This session will feature our acting CEO Scott Flora, and CFO, Jörgen Svanström, who will share insights into the company’s strategic direction and upcoming initiatives. A warm welcome to join us to learn more about Integrum’s next steps. When: 25 September 2024 @3pm-3.30pm Where: https://www.finwire.tv/webcast/integrum/integrum-meeting/ We look forward to seeing you online!

Inger Rydin is appointed interim COO and takes office immediately

Integrum AB (publ), the medical technology company that improves the lives of amputees, announces that Inger Rydin has been appointed interim COO and will be responsible for operations at the office in Mölndal, Sweden. Inger, who served as interim COO at Integrum from 2021 to 2023, will be part of the management team. She takes office immediately.“Inger Rydin is a senior and experienced leader who knows Integrum well. She is warmly welcomed to the management team. I look forward to working with Inger to create a value-driven organization that primarily focuses on the growth opportunities in

The board of Integrum appoints Scott Flora as acting CEO

Integrums CEO Rickard Brånemark has today agreed together with the board that he will leave the CEO role. The board announces that Scott Flora, board member since 2023, has been appointed acting CEO of Integrum AB. He takes office with immediate effect. The board will immediately start the recruiting process of a new CEO. Rickard Brånemark is appointed Chief Scientific Advisor.Rickard Brånemark is the company's founder and board member. Rickard remains in the company in a new role as Chief Scientific Advisor. In his new role, he will provide support around the safe and effective use of

Focus on long-term growth creates setback in sales

FIRST QUARTER 2024/25 (MAY – JULY) · Net sales amounted to 18.5 (20.4) MSEK, which is a decrease of 9.5% compared with the corresponding period last year. · Operating profit amounted to -12.0 (-2.9) MSEK. The operating result amounted to -10.6 MSEK excluding currency effects of -1.4 MSEK, most of which are unrealized internal accounts receivables. · Profit/loss after tax amounted to  -9.4 (-2.9) MSEK, which resulted in earnings per share of SEK -0.49 (-0.1). · Cash flow from operating activities amounts to -10.5 MSEK (-2.6), change in working capital was -3.5 MSEK (-7.1) and

Integrum AB: Invitation to the First Quarter 2024/25 Results Presentation

Mölndal, Sweden – August 26, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a webcast presentation of its first quarter 2024/25 results on August 29, 2024 at 14:00 CEST.Integrum’s CEO Rickard Brånemark will present the report together with CFO Jörgen Svanström and US President Jeffrey Zanni in a webcast. The presentation will be held in English. Time: Thursday, August 29, 2024 at 14:00 CEST. Location: Webcast (see link below). The report will be available at https://integrum.se/investor-relations/financial-reports-calendar/ The webcast and

Integrum has carried out a directed new issue of 961,539 series B shares, raising proceeds of approximately SEK 50 million

Mölndal, Sweden – 13 June 2024 – Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) (“Integrum” or the “Company”) has successfully carried out an issue of 961,539 new series B shares, at a subscription price of SEK 52 per share, raising proceeds of approximately SEK 50 million (the “Directed Issue”).The Board of Directors of Integrum has, in accordance with the issue authorization granted by the annual general meeting on 27 September 2023, and as indicated in the press release by the Company earlier today, resolved on a directed issue of 961,539 new series B shares at a

Integrum intends to carry out a directed new issue of series B shares of approximately SEK 50 million

Mölndal, Sweden – 13 June 2024 – Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) (“Integrum” or the “Company”) announces its intention to carry out an issue of series B shares of approximately SEK 50 million directed to Swedish and international institutional investors (the “Directed Issue”). Integrum has appointed Carnegie Investment Bank AB (publ) (“Carnegie”) as Sole Global Coordinator and Bookrunner to explore the conditions to carry out the Directed Issue through an accelerated book-building procedure.The Directed Issue is intended to be carried out with deviation from

Integrum signs Memorandum of Understanding with Coapt for the use of its pattern recognition technology with the e-OPRA[TM] Implant System

Mölndal, Sweden – June 13, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company has entered a Memorandum of Understanding with the American medtech company Coapt LLC, with the intention to provide Integrum the possibility to combine Coapt’s pattern recognition technology with the continued development of e-OPRA[TM] Implant System.Coapt is the leading developer of advanced control solutions for prosthetics. Their primary product is a pattern recognition intent decoder system, called Complete Control, designed to enhance the functionality and user

Integrum enters collaboration and distribution agreement with Hanger – the leading provider of amputee care and prosthetics in the US

Mölndal, Sweden – June 10, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has entered a commercial collaboration and distribution agreement with Hanger, the leading provider of amputee care and prosthetics in the US that delivers care to almost one-third of all amputees in the country. Within the framework of the agreement, Integrum’s prosthetic product portfolio will be made available to eligible patients at any of Hanger Clinic’s 900 patient care facilities nationwide as well as distributed to other facilities. The agreement will take

A Record Year in Sales

FOURTH QUARTER 2023/24 (FEBRUARY – APRIL) · Net sales amount to 26.1 (18.1) MSEK, which is an increase of 43.7% compared with the corresponding period last year. The growth in the US market and in Rest of the World is 15.1% and 147 % compared with the corresponding period last year, respectively. · Operating result amounts to 2.6 (-7.2) MSEK (EBIT 10.1%). The operating result amounted to -1.8 MSEK (EBIT -7.0%) excluding currency effects of 4.5 MSEK, most of which are unrealized internal accounts receivables. · Profit/loss after tax amounted to 2.3 (-6.1) MSEK, which resulted in

Integrum receives market approval for OPRA[® in Israel]

Mölndal, Sweden – May 29, 2024 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company has received market approval for the OPRA[®] Implant System in Israel.In March, Integrum entered a commercial agreement with AMI Technologies to Introduce the OPRA® Implant System to the Israeli market. With the market approval in place, AMI Technologies can now start providing OPRA® to hospitals in the region. "There is a large need for innovative products in the region, and we appreciate the rapid regulatory approval making it possible to soon offer our life-changing

Integrum AB: Invitation to the Fourth Quarter 2023/24 Results Presentation

Mölndal, Sweden – May 24, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a webcast presentation of its fourth quarter 2023/24 results on May 30, 2024 at 14:00 CEST.Integrum’s CEO Rickard Brånemark will present the report together with CFO Jörgen Svanström and US President Jeffrey Zanni in a webcast. The presentation will be held in English. Time: Thursday, May 30, 2024 at 14:00 CEST. Location: Webcast (see link below). The report will be available at https://integrum.se/investor-relations/financial-reports-calendar/ The webcast and presentation

Integrum has been granted a registered trademark for OPRA® Implant System in the EU

Mölndal, Sweden – May 15, 2024 — Integrum (publ) (Nasdaq First North Growth Marketing: INTEG B) announces that the European Union Intellectual Property Office, EUIPO, has approved Integrum’s product registration application for the OPRA® Implant System.Until now, the OPRA® Implant system has been an unregistered mark without legal protection. As it is granted a registered trademark, Integrum now obtains unitary immaterial protection for the product in the entire territory of the EU. “We are very pleased to have obtained a registered trademark for OPRA®[ ]as it grants us legal

Integrum launches short video documentary to showcase the company’s efforts to treat combat amputees in Ukraine

Mölndal, Sweden – May 3, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company has launched a short video documentary about the company’s Center of Excellence in Kyiv, Ukraine. During Dr Rickard Brånemark’s latest training session at the end of April, the center was visited by several delegations with politicians, company leaders and military representatives, and the video documentary was screened to introduce discussions on the future of trauma healthcare in Ukraine. Among the visitors were the Swedish Minister for Social Services, Camilla

Integrum expands its product offering to the United Kingdom market

Mölndal, Sweden – May 2, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company has entered a commercial agreement with LEDA Orthopaedics Ltd., a local medical device distributor specialized in niche trauma implants, hand surgery prostheses and unique solutions for orthopaedic procedures, to introduce OPRA[TM] Implant System in the United Kingdom.As part of Integrum's efforts to expand the availability of the OPRA™ Implant System to new geographical markets, the company has as of today initiated a distribution agreement in the United Kingdom with LEDA

Integrum expands its product offering into the Israeli market

Mölndal, Sweden – March 26, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company has entered a commercial agreement with AMI Technologies, a leading local medical device distributor, to introduce the OPRA[TM] Implant System in Israel.As part of Integrum's efforts to expand the availability of the OPRA™ Implant System to new geographical markets, the company has as of today started a collaboration in Israel with AMI Technologies (www.ami.co.il). “The collaboration with AMI Technologies secures a swift launch of OPRA™ Implant System in Israel and

Health economic study shows positive outcome using Integrum’s OPRA[TM] Implant System over socket prostheses in transfemoral amputees

Mölndal, Sweden – March 19, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that a team of independent researchers, from six prestigious academic and clinical institutions in the US, have published a health economic article analyzing potential effects on societal cost-control and quality-of-life when utilizing osseointegrated transfemoral prostheses compared to traditional socket prostheses. The study’s meta-analyses show that costs associated with maintaining functional socket prosthesis usage exceed those of using osseointegration alternatives several times

CORRECTION A new record revenue quarter with 61% growth

The figures for Rights of Use assets (6,620 KSEK) were missing in the previous report and have now been added. The total sums for Fixed Assets and the Balance Sheet remain the same. THIRD QUARTER 2023/24 (NOV – JAN) · Net sales amounts to 30.1 (18.7) MSEK, which is an increase of 61% compared with the corresponding period last year. The growth in the US market is 43% compared with the corresponding period last year. · Operating profit amounts to 0.3 (-13.8) MSEK (EBIT 1.1%). The operating profit amounted to 6.1 MSEK (EBIT 20.2%) excluding currency effects of -5.7 MSEK, most of

A new record revenue quarter with 61% growth

THIRD QUARTER 2023/24 (NOV – JAN) · Net sales amounts to 30.1 (18.7) MSEK, which is an increase of 61% compared with the corresponding period last year. The growth in the US market is 43% compared with the corresponding period last year. · Operating profit amounts to 0.3 (-13.8) MSEK (EBIT 1.1%). The operating profit amounted to 6.1 MSEK (EBIT 20.2%) excluding currency effects of -5.7 MSEK, most of which are unrealized internal accounts receivables. · Profit/loss after tax amounts to 0.8 (-13.6) MSEK, which resulted in profit per share of SEK 0.05 (-0.74). · Cash flow from

Integrum AB: Invitation to the Third Quarter 2023/24 Results Presentation

Mölndal, Sweden – February 23, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a webcast presentation of its third quarter 2023/24 results on February 29, 2024 at 14:00 CEST.Integrum’s CEO Rickard Brånemark will present the report together with CFO Jörgen Svanström and US President Jeffrey Zanni in a webcast. The presentation will be held in English. Time: Thursday, February 29, 2024 at 14:00 CEST. Location: Webcast (see link below). The report will be available at https://integrum.se/investor-relations/financial-reports-calendar/ The webcast and

Integrum has sold and delivered OPRA[TM] Implant Systems to a value of SEK 3.5 million to Center of Excellence in Ukraine

Mölndal, Sweden – January 31, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company today has sold and delivered OPRA™ Implant Systems to a value of SEK 3.5 million to Center of Excellence at the Center for Complex Endoprosthetics, Osseointegration and Bionics in Kyiv, Ukraine.Integrum helped establish the Center of Excellence in December 2023, and two senior surgeons have been trained and certified to perform surgeries on both transfemoral and transhumeral amputees using Integrum’s innovative OPRA™ Implant System. Following a successful establishment,

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe